share_log

Aditxt Acquisition-Partner's At-Home COVID-19 Drug Fails In Late-Stage Trial

Benzinga Real-time News ·  Nov 12, 2021 13:08
  • Aditxt Inc (NASDAQ:ADTX) has announced data from Phase 3 PRESECO trial evaluating oral Avigan/Reeqonus (favipiravir) as a potential at-home therapy for mild-to-moderate COVID-19, run by Appili Therapeutics Inc.
  • The trial did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery. Additional analyses of the trial data are ongoing. 
  • Related Link: Aditxt Shares Surge On AiPharma Acquisition, Holder Of COVID-19 Candidate.
  • The trial enrolled around 1,200 patients with mild-to-moderate COVID-19 from 38 U.S., Mexico, and Brazil study sites.
  • "We are reviewing and evaluating the announced results and data and will be discussing them with AiPharma Global to determine the best course of action," stated Aditxt Co-Founder and CEO Amro Albanna.
  • Price Action: ADTX shares are down 21.60% at $1.42 during the market session on the last check Friday.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment